BlackRock
KALV

BlackRock’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.4M Buy
3,795,897
+41,749
+1% +$673K ﹤0.01% 2267
2025
Q4 		$60.6M Buy
3,754,148
+628,031
+20% +$8.32M ﹤0.01% 2400
2025
Q3 		$38.1M Sell
3,126,117
-3,377
-0.1% -$46.7K ﹤0.01% 2672
2025
Q2 		$35.4M Sell
3,129,494
-22,241
-0.7% -$272K ﹤0.01% 2667
2025
Q1 		$36.4M Buy
3,151,735
+287,739
+10% +$2.94M ﹤0.01% 2559
2024
Q4 		$24.3M Sell
2,863,996
-198,323
-6% -$2.05M ﹤0.01% 2922
2024
Q3 		$35.5M Buy
3,062,319
+117,203
+4% +$1.47M ﹤0.01% 2682
2024
Q2 		$34.7M Buy
2,945,116
+512,882
+21% +$5.99M ﹤0.01% 2641
2024
Q1 		$28.8M Buy
2,432,234
+190,209
+8% +$2.54M ﹤0.01% 2782
2023
Q4 		$27.5M Buy
2,242,025
+597,278
+36% +$5.43M ﹤0.01% 2826
2023
Q3 		$15.8M Buy
1,644,747
+45,009
+3% +$460K ﹤0.01% 3074
2023
Q2 		$14.4M Buy
1,599,738
+41,604
+3% +$384K ﹤0.01% 3227
2023
Q1 		$12.2M Sell
1,558,134
-14,287
-0.9% -$107K ﹤0.01% 3205
2022
Q4 		$10.6M Sell
1,572,421
-133,727
-8% -$716K ﹤0.01% 3369
2022
Q3 		$24.8M Buy
1,706,148
+34,653
+2% +$484K ﹤0.01% 2913
2022
Q2 		$16.4M Buy
1,671,495
+127,468
+8% +$1.41M ﹤0.01% 3192
2022
Q1 		$22.8M Buy
1,544,027
+39,407
+3% +$566K ﹤0.01% 3096
2021
Q4 		$19.9M Buy
1,504,620
+87,978
+6% +$1.4M ﹤0.01% 3276
2021
Q3 		$24.7M Sell
1,416,642
-9,780
-0.7% -$198K ﹤0.01% 3146
2021
Q2 		$34.2M Sell
1,426,422
-133,066
-9% -$3.48M ﹤0.01% 2950
2021
Q1 		$40.1M Buy
1,559,488
+446,108
+40% +$11.7M ﹤0.01% 2770
2020
Q4 		$21.1M Buy
1,113,380
+198,646
+22% +$3.41M ﹤0.01% 2977
2020
Q3 		$11.5M Sell
914,734
-9,117
-1% -$114K ﹤0.01% 3147
2020
Q2 		$11.2M Buy
923,851
+51,394
+6% +$547K ﹤0.01% 3120
2020
Q1 		$6.67M Buy
872,457
+11,824
+1% +$160K ﹤0.01% 3211
2019
Q4 		$15.3M Buy
860,633
+94,121
+12% +$1.23M ﹤0.01% 3025
2019
Q3 		$8.89M Buy
766,512
+29,730
+4% +$480K ﹤0.01% 3270
2019
Q2 		$16.3M Buy
736,782
+666,525
+949% +$15.6M ﹤0.01% 2960
2019
Q1 		$2.01M Buy
70,257
+25,179
+56% +$546K ﹤0.01% 3702
2018
Q4 		$891K Buy
45,078
+25,769
+133% +$518K ﹤0.01% 3923
2018
Q3 		$427K Buy
19,309
+3,104
+19% +$42K ﹤0.01% 4159
2018
Q2 		$132K Buy
16,205
+10,871
+204% +$96K ﹤0.01% 4407
2018
Q1 		$50K Buy
5,334
+368
+7% +$3.85K ﹤0.01% 4432
2017
Q4 		$49K Buy
4,966
+236
+5% +$2.46K ﹤0.01% 4438
2017
Q3 		$32K Buy
4,730
+399
+9% +$2.85K ﹤0.01% 4527
2017
Q2 		$32K Buy
4,331
+913
+27% +$6.71K ﹤0.01% 4587
2017
Q1 		$27K Buy
+3,418
New +$25.7K ﹤0.01% 4561

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock's KALV Position: Q1 2026 in Review

BlackRock increased its KalVista Pharmaceuticals (KALV) stake by 1.1% in Q1 2026, buying an estimated $673K and bringing the position to 3,795,897 shares worth $76.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

BlackRock first reported a position in KALV in Q1 2017 and has held it in 37 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • BlackRock held 3,795,897 shares of KalVista Pharmaceuticals worth $76.4M as of Q1 2026.
  • BlackRock bought 41,749 KalVista Pharmaceuticals shares in Q1 2026, an estimated $673K.
  • KalVista Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2267 holding.
  • BlackRock first reported a position in KalVista Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.